Smruti K. Patel · Quantifying T2-FLAIR Mismatch Using Geographically Weighted Regression and Predicting Molecular Status in Lower-Grade Gliomas
Follow
Article1 min read·Published Nov 2021Older

Quantifying T2-FLAIR Mismatch Using Geographically Weighted Regression and Predicting Molecular Status in Lower-Grade Gliomas

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Nov 2021 · 1 min read

In brief

In brief

This study quantifies the T2-FLAIR mismatch sign using geographically weighted regression to predict IDH-mutant 1p/19q noncodeleted gliomas from preoperative MRI. The method achieved 0.98 AUC in classifying molecular subtypes, offering an objective computational approach to supplement visual radiologic assessment of lower-grade gliomas.

Written by the GCMD Library team from the article.

Smruti K. Patel

Background And Purpose: The T2-FLAIR mismatch sign is a validated imaging sign of isocitrate dehydrogenase-mutant 1p/19q noncodeleted gliomas. It is identified by radiologists through visual inspection of preoperative MR imaging scans and has been shown to identify isocitrate dehydrogenase-mutant 1p/19q noncodeleted gliomas with a high positive predictive value. We have developed an approach to quantify the T2-FLAIR mismatch signature and use it to predict the molecular status of lower-grade gliomas. Materials And Methods: We used multiparametric MR imaging scans and segmentation labels of 108 preoperative lower-grade glioma tumors from The Cancer Imaging Archive. Clinical information and T2-FLAIR mismatch sign labels were obtained from supplementary material of relevant publications. We adopted an objective analytic approach to estimate this sign through a geographically weighted regression and used the residuals for each case to construct a probability density function (serving as a residual signature). These functions were then analyzed using an appropriate statistical framework. Results: We observed statistically significant (P value = .05) differences between the averages of residual signatures for an isocitrate dehydrogenase-mutant 1p/19q noncodeleted class of tumors versus other categories. Our classifier predicts these cases with area under the curve of 0.98 and high specificity and sensitivity. It also predicts the T2-FLAIR mismatch sign within these cases with an un

Statements in this article

  1. The T2-FLAIR mismatch sign is a validated imaging sign of isocitrate dehydrogenase-mutant 1p/19q noncodeleted gliomas.

    EstablishedBackground And Purpose
  2. The T2-FLAIR mismatch sign identifies isocitrate dehydrogenase-mutant 1p/19q noncodeleted gliomas with a high positive predictive value.

    EstablishedBackground And Purpose
  3. Geographically weighted regression can be used to estimate the T2-FLAIR mismatch sign objectively from multiparametric MR imaging scans.

    ResearchMaterials And Methods
  4. Statistically significant differences (P value = .05) exist between the averages of residual signatures for isocitrate dehydrogenase-mutant 1p/19q noncodeleted tumors versus other categories.

    ResearchResults
  5. The classifier predicts isocitrate dehydrogenase-mutant 1p/19q noncodeleted cases with area under the curve of 0.98 and high specificity and sensitivity.

    ResearchResults

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
Only a few other public items share this field — go deeper there →
GCMD Library — educational content from recorded physician discussions, not medical advice.